

mRNA: Therapeutics and Global Markets

Market Research Report | 2023-12-13 | 171 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope:

This report focuses on the mRNA therapeutics market. This reports include the types of mRNA and their application in therapy. Also, the report focuses on the patent analysis and clinical trial analysis of mRNA. The report also portrays the trends and dynamics affecting the market during the study period. The study covers market projections through 2028 and profiles major market players.

By geography, the market is segregated into North America, Europe, Asia-Pacific and the Rest of the World (RoW). The market is estimated through 2028.

BCC Research also summarizes the main industry acquisitions and strategic alliances from January 2020 through December 2022 and identifies the trends in this activity.

Report Includes:

- 37 data tables and 27 additional tables
- An overview of the global market related to mRNA therapeutics
- In-depth analysis of global market trends, featuring historical revenue data for 2021 and 2022, estimated figures for 2023, forecasts for 2028, and projections of compound annual growth rates (CAGRs) through 2028
- Evaluation of the current market and revenue growth prospects specific to mRNA therapeutics, accompanied by a market share analysis by therapeutic type and geographical region
- Coverage of the pandemic threats, therapeutic developments, and new technologies in the market

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

- Discussion of the advantages of mRNA over protein- and DNA-based delivery systems, demographic and economic trends, and outlook for the mRNA therapeutics market
- Information on prophylactic vaccines, vaccine discovery and development, and R&D activities
- Analysis of the various therapeutics as well as promising vaccines intended for the prevention and treatment of chronic and infectious diseases
- Assessment of regulatory structure, pricing and reimbursement scenarios, the pipeline for new molecules and therapeutics
- Market share analysis of the key companies and mergers & acquisitions, joint ventures, collaborations, and partnerships
- Profiles of leading market participants

Executive Summary

Summary:

The global market for mRNA therapeutics reached \$REDACTED billion in 2022 and is estimated to reach \$REDACTED billion by the end of 2028. It is expected to decline at the CAGR of REDACTED% during the forecast period. The decline, which stems from the end of COVID-19 pandemic, should be mitigated by the introduction of new drugs during the forecast period.

The COVID-19 pandemic created a niche market for mRNA therapeutics, particularly vaccines. Developed countries used mRNA vaccines for protection against the severe acute respiratory syndrome (SARS)-CoV-2. The fast-paced development of mRNA vaccines was possible due to advancement in sequencing as well as two decades of previous research on mRNA drugs. mRNA drugs should become a major segment of vaccines and therapeutics.

The mechanism of action of mRNA vaccine is like that elucidated by the protein-based vaccines. The mRNA particle, which is inserted into a healthy patient, carries the code for an antigen (a small piece of protein found on the virus's outer membrane). Viral proteins are produced via the mRNA code. The body recognizes it as a foreign material and produces antibodies necessary for the protection against the diseases.

Key factors driving the mRNA global market include the increasing number of pandemics and epidemic diseases. In the past 20 years, the world has experienced the two epidemics: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS); and the pandemic COVID-19. These situations highlighted the need for technologies like mRNA that are easy to produce and upscale quickly. The COVID-19 pandemic pushed mRNA therapeutics to the forefront of the pharma and bio-pharma industries.

Another key growth factor is the pharmaceutical industry's investment in the mRNA segment. Large pharmaceutical companies are seeking innovative drugs that have limited side effects. mRNA presents one such opportunity. Also, private investments are increasing in this segment, driven by the COVID-19 pandemic.

However, the market also is facing a few challenges, such as lack of standard regulations that affect a different class of therapeutics. This leads to confusion for new and existing players for which pathway to follow. Existing and new technologies, such as protein and CRISP, respectively, also pose competition.

The pipeline of mRNA drugs is robust. Under favorable conditions, a drug should enter the market by late 2024 or early 2025. Currently, the majority of drugs in the pipeline target infectious diseases or are being developed as vaccines. Also, therapeutic drugs target cancer treatment. Some drugs have received fast-track status from the FDA, increasing the pace of those clinical trials due to their promising results. Drug trials using mRNA vaccines are showing efficacy in the range of REDACTED% to REDACTED%. There are 2 influenzas vaccines which are, under phase 3 clinical trials and will be commercialized during the forecast period.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Table of Contents:

- Table of Contents
- Chapter 1 Introduction
 - Study Goals and Objectives
 - Reasons for Doing This Study
 - Scope of Report
 - What's New in This Update?
 - Methodology
 - Information Sources
 - Geographic Breakdown
 - Segmentation Breakdown
- Chapter 2 Summary and Highlights
 - Market Outlook
 - Market Summary
- Chapter 3 Market Overview
 - Evolution of RNA Therapeutics
 - History of RNA Therapeutics
 - Development of RNA Therapeutics and Types
 - DNA Therapeutics vs. RNA Therapeutics
 - Clinical Need for RNA Therapeutics
 - Increasing Disease Population and Economic Burden
 - Limitations of Traditional Therapeutics
 - Therapeutic Limitations of Biologics
 - Poor Management of Chronic Diseases
 - Limited Treatment for Rare Diseases
 - RNA Therapeutics
 - Antisense Oligonucleotide (ASO) as Therapeutics
 - Small Interfering RNA (siRNA) as Therapeutics
 - miRNA as Therapeutics
 - Aptamers as Therapeutics
 - mRNA as Therapeutics
 - Manufacturing RNA-Based Biopharmaceuticals
 - Chromatographic Purification Steps
 - Delivery of RNA Therapeutics
 - Polymer Conjugation/Chemical Modification
 - Encapsulation
 - Lipid-Based Nanoparticles
 - Polymer Nanomaterials
 - Silica Nanoparticles
 - Carbon and Gold Nanomaterials
 - GaINAc
 - Institution and Hospital-Based RNA Therapeutics
 - Regulatory Influence on the Market for RNA Therapeutics
 - Impact of COVID-19
- Chapter 4 Market Dynamics
 - Market Dynamics
 - Drivers

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Restraints
Opportunities
Chapter 5 Target Disease and Disorders
Overview of Common Diseases and Disorders for mRNA Therapeutics
Cancer
Infectious Diseases
Cardiovascular Disease
Lifestyle Disorders
Respiratory Disorders
Musculoskeletal Disorders
Gastrointestinal Disorders
Urology Disorders
Nephrology Disorders
Immune Disorders
Neurological Disorders
Rare Diseases
Other Disorders
Tobacco Smoking and Associated Diseases
Infectious Diseases: COVID-19 Pandemic and mRNA Therapeutics
Chronic Diseases: Expanding Horizon for mRNA Therapeutics
Unmet Needs of Rare Diseases: mRNA Therapeutics
Aging, Gender and Onset of Diseases
Global Demographics
U.S. Demographics
European Demographics
Japanese Demographics
Chapter 6 Pipeline and Clinical Trial Analysis
mRNA Vaccines
mRNA Therapeutics
Clinical Trial Analysis
Chapter 7 Market Breakdown by Product
Mechanism of Action of mRNA COVID Vaccines
Three Most-Advanced mRNA Vaccines
Chapter 8 Market Breakdown by Region
North America
Canada
Europe
Asia-Pacific
Japan
South Korea
China
India
Australia
RoW
Chapter 9 Emerging Technologies and Developments
Overview
Nanoparticles

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Modified mRNA
Automated mRNA Synthesis Kits
Bio Platforms
Chapter 10 Patent Analysis
Patent Analysis
mRNA Publication
Chapter 11 Outlook for Mergers & Acquisitions, and Venture Funding
Chapter 12 Competitive Intelligence
Chapter 13 Company Profiles
ARCTUR U.S. THERAPEUTICS INC.
BIONTECH SE
CUREVAC N.V.
GENNOVA BIOPHARMACEUTICALS LTD.
MERCK KGAA
MODERNA INC.
NUTCRACKER THERAPEUTICS
OMEGA THERAPEUTICS INC.
STRAND THERAPEUTICS
VAXESS TECHNOLOGIES INC.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

mRNA: Therapeutics and Global Markets

Market Research Report | 2023-12-13 | 171 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-04"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

